CANCER FACT SHEET 2023
OVARIAN CANCER
ICD-10 C56

Belgian Cancer Registry

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*(1.05)^5).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

TABLE OF CONTENTS

Belgian Cancer Registry

1.1. Ovarian cancer incidence: by region

1.1.1. Ovarian cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Females																						
Belgium	0	0	5	3	8	3	10	9	24	22	30	53	75	108	91	124	66	52	20	3	706	11.2
	[0.0]	[0.0]	[1.5]	[0.9]	[2.4]	[0.8]	[2.6]	[2.4]	[6.2]	[6.0]	[7.7]	[13.3]	[19.6]	[31.9]	[30.6]	[50.5]	[37.9]	[38.9]	[28.2]	[14.4]	[11.9]	(10.4; 12.0)
Brussels	0	0	1	0	0	0	2	1	5	3	4	7	5	13	9	5	6	3	0	0	64	12.6
	[0.0]	[0.0]	[2.6]	[0.0]	[0.0]	[0.0]	[3.7]	[2.1]	[11.0]	[7.3]	[10.5]	[20.5]	[16.5]	[52.0]	[42.0]	[27.8]	[46.7]	[30.6]	[0.0]	[0.0]	[10.1]	(9.4; 15.7)
Flanders	0	0	2	2	7	2	4	8	10	6	11	27	51	53	50	80	48	40	12	2	415	10.8
	[0.0]	[0.0]	[1.0]	[1.1]	[3.8]	[1.0]	[1.8]	[3.8]	[4.5]	[2.9]	[4.9]	[11.4]	[22.3]	[26.2]	[28.5]	[53.2]	[43.9]	[46.9]	[27.3]	[16.3]	[12.1]	(9.7; 11.8)
Wallonia	0	0	2	1	1	1	4	0	9	13	15	19	19	42	32	39	12	9	8	1	227	11.5
	[0.0]	[0.0]	[1.8]	[0.9]	[0.9]	[0.9]	[3.3]	[0.0]	[7.6]	[11.0]	[12.0]	[15.0]	[15.4]	[37.7]	[32.0]	[50.4]	[23.1]	[23.3]	[37.7]	[15.4]	[12.1]	(10.0; 13.0)

1.2. Ovarian cancer incidence: by tumour stage

1.2.1. Ovarian cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	43 [1.5]	88 [6.2]	34 [5.3]	168 [2.8]	2.7 (2.3; 3.2)
II	13 [0.4]	11 [0.8]	6 [0.9]	30 [0.5]	0.5 (0.3; 0.7)
III	23 [0.8]	106 [7.5]	87 [13.5]	216 [3.6]	3.4 (3.0; 3.9)
IV	15 [0.5]	91 [6.4]	109 [16.9]	216 [3.6]	3.3 (2.9; 3.7)
X/NA	15 [0.5]	31 [2.2]	29 [4.5]	76 [1.3]	1.2 (0.9; 1.5)

1.2.2. Ovarian cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	52 [1.8]	85 [6.0]	39 [6.0]	180 [3.0]	3.0 (2.5; 3.4)
II	5 [0.2]	22 [1.6]	8 [1.2]	35 [0.6]	0.6 (0.4; 0.8)
III	36 [1.2]	98 [6.9]	56 [8.7]	191 [3.2]	3.1 (2.7; 3.6)
IV	7 [0.2]	37 [2.6]	32 [5.0]	76 [1.3]	1.2 (0.9; 1.5)
X/NA	9 [0.3]	85 [6.0]	130 [20.1]	224 [3.8]	3.3 (2.9; 3.8)

1.2.3. Ovarian cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	N[CR]				ESR2013 (95%CI)
	15-54	**55-74**	**75+**	**All ages**	
I	53 [1.8]	84 [5.9]	40 [6.2]	181 [3.0]	3.0 (2.5; 3.4)
II	4 [0.1]	20 [1.4]	7 [1.1]	31 [0.5]	0.5 (0.3; 0.7)
III	30 [1.0]	108 [7.6]	87 [13.5]	225 [3.8]	3.6 (3.1; 4.1)
IV	18 [0.6]	100 [7.1]	113 [17.5]	232 [3.9]	3.6 (3.1; 4.0)
X/NA	4 [0.1]	15 [1.1]	18 [2.8]	37 [0.6]	0.6 (0.4; 0.8)

1.2.4. Ovarian cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Type	Grade	N[CR]				ESR2013 (95%CI)
		15-54	**55-74**	**75+**	**All ages**	
Serous carcinoma		45 [1.5]	216 [15.3]	190 [29.4]	451 [7.6]	7.1 (6.5; 7.8)
	Low-grade	9 [0.3]	16 [1.1]	7 [1.1]	32 [0.5]	0.5 (0.3; 0.7)
	High-grade	36 [1.2]	200 [14.1]	182 [28.2]	418 [7.0]	6.6 (5.9; 7.2)
	Unspecified	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
Mucinous carcinoma		18 [0.6]	26 [1.8]	16 [2.5]	60 [1.0]	1.0 (0.7; 1.2)
Endometrioid carcinoma		12 [0.4]	19 [1.3]	9 [1.4]	40 [0.7]	0.7 (0.5; 0.9)
Clear-cell carcinoma		6 [0.2]	19 [1.3]	2 [0.3]	27 [0.5]	0.5 (0.3; 0.6)
Adenocarcinoma		4 [0.1]	7 [0.5]	12 [1.9]	23 [0.4]	0.3 (0.2; 0.5)
Other and unspecified		24 [0.8]	40 [2.8]	36 [5.6]	105 [1.8]	1.6 (1.3; 1.9)

1.2.5. Ovarian cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Type	Grade	Stage	N[CR] 15-54	55-74	75+	All ages	ESR2013 (95%CI)
Serous carcinoma		I	3 [0.1]	15 [1.1]	15 [2.3]	33 [0.6]	0.5 (0.3; 0.7)
		II	2 [0.1]	10 [0.7]	6 [0.9]	18 [0.3]	0.3 (0.2; 0.4)
		III	25 [0.9]	97 [6.9]	68 [10.5]	190 [3.2]	3.1 (2.6; 3.5)
		IV	14 [0.5]	86 [6.1]	90 [13.9]	190 [3.2]	2.9 (2.5; 3.4)
		X/NA	1 [0.0]	8 [0.6]	11 [1.7]	20 [0.3]	0.3 (0.2; 0.4)
	Low-grade	I	0 [0.0]	2 [0.1]	1 [0.2]	3 [0.1]	0.0 (0.0; 0.1)
		II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		III	7 [0.2]	10 [0.7]	4 [0.6]	21 [0.4]	0.3 (0.2; 0.5)
		IV	2 [0.1]	2 [0.1]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
		X/NA	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
	High-grade	I	3 [0.1]	13 [0.9]	14 [2.2]	30 [0.5]	0.5 (0.3; 0.6)
		II	2 [0.1]	10 [0.7]	6 [0.9]	18 [0.3]	0.3 (0.2; 0.4)
		III	18 [0.6]	87 [6.2]	64 [9.9]	169 [2.8]	2.7 (2.3; 3.1)
		IV	12 [0.4]	84 [5.9]	88 [13.6]	184 [3.1]	2.9 (2.4; 3.3)
		X/NA	1 [0.0]	6 [0.4]	10 [1.5]	17 [0.3]	0.3 (0.1; 0.4)
	Unspecified	I	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		X/NA	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
Mucinous carcinoma		I	16 [0.5]	19 [1.3]	9 [1.4]	44 [0.7]	0.7 (0.5; 0.9)
		II	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)

Type	Grade	Stage	N[CR]				ESR2013 (95%CI)
			15-54	55-74	75+	All ages	
		III	1 [0.0]	1 [0.1]	5 [0.8]	7 [0.1]	0.1 (0.0; 0.2)
		IV	1 [0.0]	2 [0.1]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
		X/NA	0 [0.0]	3 [0.2]	0 [0.0]	3 [0.1]	0.0 (0.0; 0.1)
Endometrioid carcinoma		I	11 [0.4]	15 [1.1]	5 [0.8]	31 [0.5]	0.5 (0.3; 0.7)
		II	1 [0.0]	2 [0.1]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)
		III	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)
		IV	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
		X/NA	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
Clear-cell carcinoma		I	4 [0.1]	14 [1.0]	2 [0.3]	20 [0.3]	0.3 (0.2; 0.5)
		II	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
		III	2 [0.1]	1 [0.1]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)
		IV	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
		X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Adenocarcinoma		I	3 [0.1]	2 [0.1]	2 [0.3]	7 [0.1]	0.1 (0.0; 0.2)
		II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		III	1 [0.0]	2 [0.1]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.2)
		IV	0 [0.0]	2 [0.1]	6 [0.9]	8 [0.1]	0.1 (0.0; 0.2)
		X/NA	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
Other and unspecified		I	16 [0.5]	19 [1.3]	7 [1.1]	46 [0.8]	0.7 (0.5; 1.0)
		II	1 [0.0]	5 [0.4]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
		III	1 [0.0]	6 [0.4]	11 [1.7]	18 [0.3]	0.3 (0.1; 0.4)
		IV	3 [0.1]	7 [0.5]	13 [2.0]	24 [0.4]	0.4 (0.2; 0.5)
		X/NA	3 [0.1]	3 [0.2]	4 [0.6]	10 [0.2]	0.2 (0.1; 0.2)

2.1. Ovarian cancer incidence trends: by region

2.1.1. Ovarian cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	911	931	921	923	876	784	860	830	801	775	836	802	733	769	741	713	813	804	751	706		
	CR	17.2	17.5	17.2	17.1	16.1	14.3	15.6	14.9	14.2	13.7	14.7	14.1	12.8	13.4	12.8	12.3	13.9	13.8	12.8	11.9		
	ESR2013	17.8	17.7	17.6	17.4	16.2	14.3	15.6	14.9	14.2	13.6	14.5	13.9	12.5	13.1	12.4	11.8	13.4	13.2	12.1	11.2	-2.2 (-2.6; -1.8)	2004-2023
Brussels	**N**	73	87	63	76	78	62	77	74	64	48	75	60	61	59	61	56	76	87	60	64		
	CR	14.1	16.6	11.9	14.2	14.4	11.2	13.7	12.8	10.9	8.1	12.6	10.0	10.0	9.7	10.0	9.1	12.2	14.0	9.6	10.1		
	ESR2013	16.2	18.7	13.9	15.8	16.2	13.8	15.9	14.8	12.6	9.5	14.8	12.7	11.9	12.1	12.1	10.9	15.3	16.7	11.9	12.6	-1.4 (-2.5; -0.1)	2004-2023
Flanders	**N**	561	557	581	544	534	476	505	507	484	473	485	491	442	475	459	439	488	474	477	415		
	CR	18.4	18.2	18.9	17.5	17.1	15.1	15.9	15.9	15.1	14.6	14.9	15.1	13.5	14.4	13.9	13.2	14.6	14.1	14.1	12.1		
	ESR2013	18.8	18.1	18.8	17.4	16.7	14.7	15.4	15.4	14.5	14.0	14.1	14.3	12.7	13.4	12.9	12.1	13.3	12.8	12.8	10.8	-2.4 (-2.8; -2.0)	2004-2023
Wallonia	**N**	277	287	277	303	264	246	278	249	253	254	276	251	230	235	221	218	249	243	214	227		
	CR	15.9	16.4	15.8	17.1	14.8	13.8	15.5	13.7	13.9	13.9	15.0	13.6	12.5	12.7	11.9	11.7	13.4	13.0	11.4	12.1		
	ESR2013	16.5	17.0	16.3	17.6	15.3	13.8	15.9	13.8	14.1	14.1	15.2	13.5	12.2	12.6	11.5	11.3	13.2	12.6	10.9	11.5	-2.2 (-2.7; -1.7)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Ovarian cancer incidence trends: by tumour stage

2.2.1. Ovarian cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	147	159	185	172	181		
	CR	2.5	2.7	3.2	2.9	3.0		
	ESR2013	2.5	2.7	3.1	2.9	3.0	0.5 (-0.4; 1.5)	2004-2023
II	N	37	49	51	42	31		
	CR	0.6	0.8	0.9	0.7	0.5		
	ESR2013	0.6	0.8	0.8	0.7	0.5	-1.8 (-3.4; -0.2)	2004-2023
III	N	218	247	249	268	225		
	CR	3.8	4.2	4.3	4.6	3.8		
	ESR2013	3.6	4.1	4.1	4.3	3.6	-0.4 (-1.1; 0.3)	2004-2023
							1.2 (-0.1; 2.4)	2004-2015
							-2.5 (-4.2; -0.7)	2016-2023
IV	N	232	265	274	234	232		
	CR	4.0	4.5	4.7	4.0	3.9		
	ESR2013	3.8	4.4	4.5	3.7	3.6	2.4 (1.4; 3.3)	2004-2023
X/NA	N	79	93	45	35	37		
	CR	1.4	1.6	0.8	0.6	0.6		
	ESR2013	1.2	1.4	0.7	0.5	0.6	-13.1 (-14.6; -11.5)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Ovarian cancer incidence trends: by age group

2.3.1. Ovarian cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, %	(95%CI)	Period
15-54	N	209	228	201	219	185	162	175	157	189	160	156	154	155	144	150	142	131	153	127	109			
	CR	7.4	8.1	7.1	7.7	6.5	5.6	6.1	5.4	6.5	5.5	5.4	5.3	5.3	5.0	5.2	4.9	4.5	5.3	4.4	3.7			
	ESR2013	7.7	8.2	7.2	7.8	6.5	5.7	6.1	5.4	6.5	5.5	5.3	5.3	5.3	5.0	5.2	4.9	4.6	5.4	4.5	3.8	-3.0	(-3.7; -2.4)	2004-2023
55-74	N	459	419	459	446	424	376	422	382	371	369	393	385	340	385	335	331	388	377	370	327			
	CR	41.9	38.0	41.4	39.9	37.6	33.0	36.5	32.5	31.1	30.4	32.0	30.8	26.7	29.5	25.2	24.4	28.2	27.0	26.4	23.1			
	ESR2013	42.0	37.6	41.4	40.1	37.7	33.2	36.7	32.9	31.5	30.8	32.6	31.6	27.2	30.1	25.4	24.7	28.4	27.2	26.5	23.2	-2.8	(-3.3; -2.3)	2004-2023
75+	N	242	281	261	252	266	241	263	282	239	244	285	261	235	239	252	237	292	270	253	265			
	CR	46.6	52.9	47.9	45.2	46.7	41.7	44.8	47.5	39.8	40.4	46.7	42.3	38.1	39.0	41.2	38.6	47.1	43.6	39.9	41.1			
	ESR2013	46.0	52.8	47.5	44.6	46.0	40.7	44.4	47.9	40.0	40.5	47.1	42.7	38.6	39.4	41.7	38.5	49.6	44.9	40.6	42.3	-0.7	(-1.3; 0.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Ovarian cancer prevalence: by region

3.1.1. Ovarian cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023

Region		Females				
		1-year	**5-year**	**10-year**	**15-year**	**20-year**
Belgium	N	586	2,299	3,589	4,545	5,486
	CR	9.8	38.5	60.2	76	92
	ESR2013	9.3	36.7	57.2	72.3	86.8
Brussels	N	53	215	318	398	470
	CR	8.3	33.7	49.9	62.4	73.7
	ESR2013	10.2	41.0	61.0	75.9	89.6
Flanders	N	339	1,389	2,194	2,792	3,398
	CR	9.8	40.3	63.7	81.1	98.7
	ESR2013	8.9	36.9	58.2	73.9	89.4
Wallonia	N	194	695	1,077	1,355	1,618
	CR	10.3	36.9	57.1	71.9	85.8
	ESR2013	9.8	35.1	54.2	68.0	80.8

Belgian Cancer Registry

4.1. Ovarian cancer survival: by region

4.1.1. Ovarian cancer survival by region and age group: number at risk and net survival probabilities, 2014-2023

			Net Survival Probability, 2014-2023			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Females						
Belgium	**All ages**	7,607	78.3% (77.4%; 79.3%)	58.1% (56.9%; 59.4%)	46.2% (44.8%; 47.6%)	36.1% (33.9%; 38.3%)
	15-54	1,282	93.5% (92.1%; 94.8%)	81.3% (79.1%; 83.5%)	72.1% (69.5%; 74.9%)	61.3% (57.9%; 65.0%)
	55-74	3,617	86.7% (85.6%; 87.8%)	64.6% (63.0%; 66.3%)	49.4% (47.6%; 51.4%)	36.5% (34.1%; 39.1%)
	75+	2,578	58.5% (56.5%; 60.6%)	36.9% (34.7%; 39.2%)	27.6% (25.2%; 30.1%)	21.9% (17.4%; 27.6%)
Brussels	**All ages**	650	80.8% (77.7%; 84.1%)	63.3% (59.3%; 67.6%)	49.8% (45.2%; 54.8%)	31.3% (21.6%; 45.5%)
	15-54	167	94.0% (90.3%; 97.7%)	82.3% (76.4%; 88.6%)	72.0% (64.6%; 80.2%)	64.4% (55.6%; 74.6%)
	55-74	290	83.4% (79.2%; 88.0%)	65.2% (59.6%; 71.4%)	47.3% (41.0%; 54.6%)	33.0% (25.1%; 43.5%)
	75+	183	64.4% (57.3%; 72.4%)	43.7% (35.8%; 53.2%)	33.8% (25.3%; 45.2%)	8.8% (2.1%; 36.3%)
Flanders	**All ages**	4,610	78.2% (76.9%; 79.5%)	58.8% (57.2%; 60.4%)	47.0% (45.2%; 48.8%)	38.6% (36.0%; 41.4%)
	15-54	682	93.8% (92.0%; 95.7%)	81.6% (78.7%; 84.7%)	73.7% (70.2%; 77.4%)	63.3% (58.8%; 68.1%)
	55-74	2,185	87.6% (86.2%; 89.1%)	66.4% (64.3%; 68.6%)	51.6% (49.2%; 54.1%)	38.5% (35.4%; 42.0%)
	75+	1,652	58.6% (56.1%; 61.2%)	38.8% (36.1%; 41.8%)	28.9% (25.8%; 32.2%)	27.4% (21.9%; 34.3%)
Wallonia	**All ages**	2,347	78.0% (76.2%; 79.7%)	55.3% (53.2%; 57.6%)	43.5% (41.2%; 46.0%)	32.2% (29.0%; 35.6%)
	15-54	433	92.7% (90.2%; 95.2%)	80.4% (76.6%; 84.4%)	69.6% (65.0%; 74.6%)	57.2% (50.9%; 64.2%)

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	55-74	1,142	85.7% (83.7%; 87.9%)	61.1% (58.2%; 64.2%)	45.9% (42.7%; 49.3%)	33.5% (29.6%; 38.0%)
	75+	743	57.1% (53.4%; 61.0%)	31.0% (27.4%; 35.1%)	23.2% (19.5%; 27.8%)	13.8% (8.5%; 22.2%)

4.2. Ovarian cancer survival: by tumour type and tumour stage

4.2.1. Ovarian cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2014-2023

Type	Grade	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2014-2023					
Ovary		All	7,607	78.3% (77.4%; 79.3%)	67.5% (66.4%; 68.7%)	58.1% (56.9%; 59.4%)	51.2% (49.9%; 52.5%)	46.2% (44.8%; 47.6%)	36.1% (33.9%; 38.3%)
		I	997	96.6% (95.1%; 98.0%)	95.0% (93.1%; 96.9%)	92.6% (90.3%; 95.1%)	89.6% (86.6%; 92.7%)	88.1% (84.6%; 91.7%)	92.4% (85.9%; 99.4%)
		II	230	84.9% (80.0%; 90.1%)	79.4% (73.7%; 85.6%)	77.0% (70.6%; 84.0%)	75.1% (68.0%; 82.9%)	68.0% (59.8%; 77.5%)	46.6% (30.4%; 71.3%)
		III	1,936	79.4% (77.5%; 81.3%)	66.2% (63.9%; 68.5%)	54.2% (51.8%; 56.8%)	43.9% (41.4%; 46.6%)	36.8% (34.1%; 39.6%)	23.6% (19.9%; 28.0%)
		IV	2,025	64.6% (62.5%; 66.8%)	47.8% (45.6%; 50.2%)	32.9% (30.8%; 35.3%)	24.9% (22.8%; 27.1%)	18.3% (16.3%; 20.5%)	9.7% (7.5%; 12.5%)
		X/NA	2,424	80.8% (79.2%; 82.5%)	72.7% (70.8%; 74.6%)	66.3% (64.2%; 68.4%)	61.0% (58.8%; 63.2%)	57.4% (55.1%; 59.8%)	46.3% (42.7%; 50.2%)
Serous carcinoma		All	4,824	81.5% (80.3%; 82.7%)	68.2% (66.8%; 69.7%)	56.1% (54.5%; 57.7%)	46.1% (44.5%; 47.8%)	39.6% (37.9%; 41.3%)	25.0% (22.8%; 27.4%)
		I	296	98.1% (95.8%; 100.4%)	96.0% (92.8%; 99.3%)	91.0% (86.4%; 95.7%)	85.1% (79.1%; 91.6%)	83.7% (76.9%; 91.0%)	82.1% (69.2%; 97.4%)
		II	136	91.2% (86.1%; 96.6%)	82.5% (75.7%; 90.0%)	78.7% (71.0%; 87.1%)	73.1% (64.4%; 83.0%)	64.4% (54.6%; 75.8%)	34.2% (16.2%; 72.2%)
		III	1,548	85.4% (83.5%; 87.3%)	71.7% (69.3%; 74.2%)	59.1% (56.4%; 61.9%)	47.1% (44.2%; 50.1%)	38.8% (35.8%; 42.0%)	19.3% (15.6%; 23.9%)
		IV	1,536	73.4% (71.1%; 75.7%)	55.5% (52.9%; 58.2%)	38.9% (36.3%; 41.7%)	29.0% (26.5%; 31.8%)	22.0% (19.5%; 24.7%)	11.3% (8.5%; 14.9%)
		X/NA	1,308	81.7% (79.5%; 84.0%)	71.2% (68.6%; 73.9%)	62.1% (59.3%; 65.1%)	53.0% (50.0%; 56.1%)	47.7% (44.7%; 50.9%)	32.4% (28.7%; 36.7%)
	Low-grade	All	585	83.9% (80.8%; 87.1%)	76.1% (72.5%; 80.0%)	69.3% (65.3%; 73.6%)	59.3% (54.9%; 64.0%)	52.6% (48.0%; 57.6%)	42.8% (36.7%; 50.0%)
		I	51	99.4% (95.5%; 103.5%)	99.0% (93.7%; 104.7%)	98.7% (91.8%; 106.1%)	96.5% (85.9%; 108.5%)	94.8% (82.5%; 109.0%)	112.5% (97.9%; 129.2%)
		II	21	N<50	N<50	N<50	N<50	N<50	N<50
		III	152	86.4% (80.7%; 92.4%)	78.2% (71.3%; 85.8%)	69.1% (61.3%; 77.9%)	59.5% (51.0%; 69.4%)	48.0% (39.1%; 58.8%)	39.5% (28.7%; 54.5%)
		IV	127	68.8% (61.0%; 77.6%)	53.6% (45.3%; 63.5%)	42.4% (34.2%; 52.7%)	28.4% (20.9%; 38.5%)	19.9% (13.0%; 30.3%)	5.5% (1.5%; 19.8%)
		X/NA	234	86.4% (81.8%; 91.2%)	81.1% (75.7%; 86.8%)	76.3% (70.4%; 82.8%)	65.7% (59.1%; 73.0%)	61.6% (54.7%; 69.4%)	49.6% (40.8%; 60.4%)
	High-grade	All	4,177	81.6% (80.3%; 82.8%)	67.5% (66.0%; 69.0%)	54.5% (52.8%; 56.2%)	44.4% (42.7%; 46.2%)	37.8% (36.1%; 39.7%)	22.1% (19.8%; 24.7%)
		I	244	97.8% (95.2%; 100.5%)	95.3% (91.6%; 99.2%)	89.2% (83.9%; 94.8%)	82.5% (75.7%; 89.9%)	81.1% (73.3%; 89.6%)	75.1% (60.6%; 93.2%)
		II	114	91.2% (85.5%; 97.2%)	81.6% (74.0%; 90.0%)	77.9% (69.5%; 87.4%)	71.2% (61.5%; 82.5%)	63.5% (52.7%; 76.3%)	30.8% (14.0%; 67.7%)

				Net Survival Probability, 2014-2023					
Type	Grade	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		III	1,391	85.3% (83.3%; 87.3%)	71.1% (68.5%; 73.7%)	58.0% (55.2%; 61.1%)	45.8% (42.8%; 49.0%)	37.9% (34.8%; 41.3%)	16.8% (13.1%; 21.7%)
		IV	1,397	73.7% (71.3%; 76.1%)	55.6% (52.9%; 58.4%)	38.5% (35.8%; 41.4%)	29.0% (26.4%; 31.9%)	21.9% (19.4%; 24.8%)	11.2% (8.3%; 15.2%)
		X/NA	1,031	82.3% (79.9%; 84.9%)	70.7% (67.7%; 73.7%)	60.2% (57.0%; 63.5%)	51.1% (47.8%; 54.6%)	45.4% (42.1%; 49.0%)	29.0% (24.9%; 33.9%)
	Unspecified	All	62	54.9% (43.4%; 69.3%)	41.8% (30.6%; 57.0%)	37.1% (26.2%; 52.6%)	32.1% (21.6%; 47.6%)	30.8% (20.4%; 46.5%)	25.5% (14.8%; 43.9%)
		I	1	N<50	N<50	N<50	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	N<50	N<50	N<50
		IV	12	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50
Mucinous carcinoma		All	541	83.8% (80.6%; 87.1%)	78.6% (74.9%; 82.5%)	75.6% (71.5%; 79.8%)	74.3% (70.0%; 78.9%)	72.4% (67.8%; 77.4%)	65.6% (56.7%; 75.9%)
		I	197	98.6% (96.1%; 101.1%)	96.4% (92.4%; 100.6%)	95.9% (91.2%; 100.8%)	94.6% (89.0%; 100.5%)	93.3% (86.7%; 100.4%)	106.7% (93.8%; 121.4%)
		II	14	N<50	N<50	N<50	N<50	N<50	N<50
		III	55	63.5% (51.7%; 78.0%)	51.2% (39.0%; 67.3%)	41.6% (29.1%; 59.4%)	40.1% (27.4%; 58.7%)	41.4% (28.2%; 60.6%)	40.3% (25.5%; 63.9%)
		IV	54	36.2% (25.5%; 51.5%)	21.2% (12.6%; 35.5%)	11.4% (5.5%; 23.9%)	9.7% (4.3%; 21.6%)	5.7% (2.0%; 16.2%)	FU<10y
		X/NA	221	86.9% (82.4%; 91.7%)	83.9% (78.8%; 89.3%)	81.7% (76.2%; 87.6%)	80.7% (74.8%; 87.0%)	78.6% (72.2%; 85.6%)	66.4% (54.3%; 81.2%)
Endometrioid carcinoma		All	500	94.8% (92.6%; 97.1%)	91.8% (88.8%; 94.8%)	89.8% (86.4%; 93.4%)	87.1% (82.9%; 91.4%)	84.4% (79.7%; 89.4%)	77.1% (63.2%; 93.9%)
		I	169	100.2% (98.2%; 102.3%)	99.1% (95.6%; 102.7%)	98.9% (94.2%; 103.9%)	98.6% (92.1%; 105.6%)	99.4% (92.1%; 107.2%)	113.4% (99.0%; 130.0%)
		II	24	N<50	N<50	N<50	N<50	N<50	N<50
		III	50	85.9% (76.0%; 97.0%)	81.6% (70.3%; 94.6%)	70.2% (57.0%; 86.6%)	57.5% (43.4%; 76.3%)	55.7% (41.4%; 75.0%)	55.6% (37.3%; 82.7%)
		IV	29	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	228	95.6% (92.5%; 98.8%)	92.0% (87.9%; 96.4%)	90.4% (85.7%; 95.4%)	88.8% (83.5%; 94.4%)	86.8% (80.7%; 93.3%)	75.0% (57.8%; 97.3%)
Clear-cell carcinoma		All	332	87.6% (83.9%; 91.4%)	79.7% (75.2%; 84.5%)	74.9% (69.9%; 80.3%)	73.6% (68.3%; 79.3%)	71.2% (65.4%; 77.5%)	71.1% (62.1%; 81.3%)
		I	119	96.8% (93.2%; 100.5%)	95.5% (91.0%; 100.2%)	95.0% (89.8%; 100.4%)	93.1% (86.9%; 99.9%)	86.8% (77.5%; 97.2%)	81.4% (67.3%; 98.6%)
		II	11	N<50	N<50	N<50	N<50	N<50	N<50

| Type | Grade | cStage | N at risk | Net Survival Probability, 2014-2023 | | | | | |
				1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		III	41	N<50	N<50	N<50	N<50	N<50	N<50
		IV	30	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	131	92.3% (87.4%; 97.4%)	84.9% (78.4%; 92.0%)	79.8% (72.3%; 88.0%)	79.0% (71.1%; 87.7%)	80.3% (72.2%; 89.3%)	81.6% (68.7%; 97.0%)
Adenocarcinoma		All	356	42.3% (37.4%; 48.0%)	34.4% (29.6%; 40.0%)	25.6% (21.0%; 31.0%)	22.5% (18.0%; 28.0%)	17.1% (13.0%; 22.4%)	12.3% (7.6%; 19.9%)
		I	17	N<50	N<50	N<50	N<50	N<50	N<50
		II	2	N<50	N<50	N<50	N<50	N<50	N<50
		III	64	38.4% (28.1%; 52.5%)	29.5% (20.1%; 43.4%)	19.7% (11.5%; 33.7%)	17.0% (9.2%; 31.6%)	12.5% (5.9%; 26.4%)	FU<10y
		IV	180	35.5% (29.0%; 43.4%)	26.1% (20.2%; 33.7%)	14.1% (9.5%; 20.7%)	9.6% (5.8%; 15.9%)	2.9% (1.1%; 7.4%)	1.4% (0.3%; 5.6%)
		X/NA	93	49.5% (40.0%; 61.2%)	43.2% (33.8%; 55.4%)	40.7% (31.2%; 53.0%)	40.7% (31.0%; 53.4%)	37.7% (28.0%; 50.7%)	27.1% (14.5%; 50.7%)
Other and unspecified		All	1,063	62.6% (59.7%; 65.7%)	54.7% (51.6%; 58.0%)	49.4% (46.2%; 52.9%)	49.0% (45.7%; 52.7%)	47.5% (43.8%; 51.5%)	51.7% (45.9%; 58.3%)
		I	199	89.5% (84.9%; 94.3%)	88.5% (83.4%; 93.9%)	85.2% (78.9%; 91.9%)	82.0% (74.7%; 90.1%)	81.8% (74.0%; 90.3%)	82.8% (71.7%; 95.6%)
		II	43	N<50	N<50	N<50	N<50	N<50	N<50
		III	178	45.9% (38.9%; 54.1%)	33.6% (27.0%; 41.9%)	24.8% (18.6%; 33.0%)	23.6% (17.2%; 32.2%)	22.5% (15.0%; 33.7%)	46.9% (30.4%; 72.4%)
		IV	196	32.4% (26.3%; 39.8%)	16.9% (12.2%; 23.4%)	9.8% (6.2%; 15.5%)	9.4% (5.9%; 15.1%)	7.8% (4.6%; 13.4%)	FU<10y
		X/NA	447	70.9% (66.6%; 75.4%)	64.0% (59.4%; 69.0%)	59.9% (55.0%; 65.1%)	60.3% (55.3%; 65.7%)	58.7% (53.2%; 64.6%)	59.6% (51.4%; 69.1%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.2. Ovarian cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2014-2023

Type	Grade	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Ovary		All	7,607	78.3% (77.4%; 79.3%)	67.5% (66.4%; 68.7%)	58.1% (56.9%; 59.4%)	51.2% (49.9%; 52.5%)	46.2% (44.8%; 47.6%)	36.1% (33.9%; 38.3%)
		I	1,574	98.8% (98.0%; 99.7%)	97.4% (96.2%; 98.7%)	95.4% (93.8%; 97.0%)	93.8% (91.8%; 95.8%)	93.1% (90.8%; 95.4%)	88.9% (82.3%; 96.1%)
		II	441	92.2% (89.4%; 95.0%)	84.5% (80.8%; 88.4%)	80.1% (75.8%; 84.6%)	74.8% (69.9%; 80.0%)	69.8% (64.2%; 75.8%)	48.0% (35.6%; 64.6%)
		III	2,094	92.5% (91.2%; 93.7%)	80.3% (78.4%; 82.2%)	67.0% (64.8%; 69.3%)	55.4% (52.9%; 57.9%)	47.3% (44.7%; 50.0%)	29.1% (25.8%; 32.7%)
		IV	880	76.1% (73.3%; 79.2%)	60.3% (57.0%; 63.8%)	45.1% (41.6%; 48.8%)	35.7% (32.3%; 39.5%)	26.2% (22.9%; 30.0%)	15.3% (11.6%; 20.2%)
		X/NA	2,624	53.1% (51.2%; 55.2%)	39.0% (37.0%; 41.0%)	29.5% (27.7%; 31.5%)	24.2% (22.4%; 26.1%)	20.8% (19.0%; 22.7%)	16.1% (13.8%; 18.7%)
Serous carcinoma		All	4,824	81.5% (80.3%; 82.7%)	68.2% (66.8%; 69.7%)	56.1% (54.5%; 57.7%)	46.1% (44.5%; 47.8%)	39.6% (37.9%; 41.3%)	25.0% (22.8%; 27.4%)
		I	437	98.4% (96.7%; 100.3%)	95.3% (92.5%; 98.1%)	89.9% (86.2%; 93.9%)	86.8% (82.3%; 91.5%)	85.1% (80.1%; 90.4%)	78.9% (69.7%; 89.2%)
		II	256	95.9% (93.0%; 98.9%)	90.4% (86.1%; 94.9%)	85.6% (80.4%; 91.1%)	77.2% (70.9%; 84.1%)	72.6% (65.5%; 80.4%)	48.5% (33.8%; 69.6%)
		III	1,781	94.7% (93.5%; 95.9%)	83.3% (81.4%; 85.3%)	69.9% (67.5%; 72.4%)	56.6% (54.0%; 59.4%)	48.1% (45.3%; 51.1%)	26.0% (22.7%; 29.8%)
		IV	715	82.2% (79.3%; 85.2%)	66.5% (62.9%; 70.3%)	50.2% (46.3%; 54.4%)	39.0% (35.1%; 43.3%)	28.8% (25.0%; 33.2%)	17.8% (13.6%; 23.1%)
		X/NA	1,635	60.0% (57.5%; 62.5%)	41.7% (39.3%; 44.4%)	29.8% (27.5%; 32.4%)	22.1% (19.9%; 24.5%)	17.8% (15.7%; 20.1%)	9.4% (7.2%; 12.3%)
	Low-grade	All	585	83.9% (80.8%; 87.1%)	76.1% (72.5%; 80.0%)	69.3% (65.3%; 73.6%)	59.3% (54.9%; 64.0%)	52.6% (48.0%; 57.6%)	42.8% (36.7%; 50.0%)
		I	91	99.4% (96.4%; 102.6%)	99.2% (94.9%; 103.6%)	94.9% (88.2%; 102.1%)	93.5% (85.3%; 102.5%)	93.9% (85.1%; 103.6%)	102.6% (89.3%; 117.9%)
		II	24	N<50	N<50	N<50	N<50	N<50	N<50
		III	198	98.2% (95.8%; 100.6%)	93.7% (89.7%; 97.9%)	87.1% (81.6%; 93.0%)	75.9% (68.9%; 83.6%)	68.1% (60.2%; 76.9%)	46.5% (35.6%; 60.9%)
		IV	66	82.7% (73.8%; 92.6%)	74.3% (64.1%; 86.1%)	67.3% (56.4%; 80.3%)	51.8% (40.3%; 66.5%)	33.1% (22.2%; 49.4%)	11.0% (3.8%; 31.6%)
		X/NA	206	62.1% (55.6%; 69.4%)	47.6% (40.9%; 55.5%)	38.7% (32.1%; 46.5%)	27.7% (21.8%; 35.3%)	22.8% (17.2%; 30.1%)	16.5% (10.7%; 25.4%)
	High-grade	All	4,177	81.6% (80.3%; 82.8%)	67.5% (66.0%; 69.0%)	54.5% (52.8%; 56.2%)	44.4% (42.7%; 46.2%)	37.8% (36.1%; 39.7%)	22.1% (19.8%; 24.7%)
		I	341	98.1% (96.0%; 100.3%)	94.0% (90.7%; 97.5%)	88.7% (84.4%; 93.4%)	85.0% (79.9%; 90.5%)	82.7% (76.9%; 89.0%)	71.3% (60.5%; 84.0%)
		II	229	95.8% (92.6%; 99.0%)	90.0% (85.3%; 94.8%)	84.5% (78.8%; 90.5%)	75.5% (68.6%; 83.1%)	70.8% (63.2%; 79.4%)	41.2% (26.0%; 65.5%)
		III	1,578	94.3% (93.0%; 95.6%)	82.0% (79.9%; 84.1%)	67.6% (65.1%; 70.3%)	54.1% (51.3%; 57.1%)	45.5% (42.6%; 48.6%)	23.6% (20.2%; 27.5%)
		IV	646	82.2% (79.1%; 85.4%)	65.8% (62.0%; 69.8%)	48.3% (44.3%; 52.8%)	37.5% (33.5%; 42.1%)	28.2% (24.2%; 32.8%)	17.4% (13.3%; 22.8%)

				Net Survival Probability, 2014-2023					
Type	Grade	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		X/NA	1,383	60.3% (57.7%; 63.1%)	41.5% (38.8%; 44.3%)	28.8% (26.3%; 31.6%)	21.5% (19.1%; 24.1%)	17.1% (14.8%; 19.7%)	8.1% (5.8%; 11.3%)
	Unspecified	All	62	54.9% (43.4%; 69.3%)	41.8% (30.6%; 57.0%)	37.1% (26.2%; 52.6%)	32.1% (21.6%; 47.6%)	30.8% (20.4%; 46.5%)	25.5% (14.8%; 43.9%)
		I	5	N<50	N<50	N<50	N<50	N<50	N<50
		II	3	N<50	N<50	N<50	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	N<50	N<50	N<50
		IV	3	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	46	N<50	N<50	N<50	N<50	N<50	N<50
Mucinous carcinoma		All	541	83.8% (80.6%; 87.1%)	78.6% (74.9%; 82.5%)	75.6% (71.5%; 79.8%)	74.3% (70.0%; 78.9%)	72.4% (67.8%; 77.4%)	65.6% (56.7%; 75.9%)
		I	342	98.5% (96.7%; 100.4%)	97.5% (94.8%; 100.2%)	97.3% (94.2%; 100.5%)	95.9% (92.1%; 99.8%)	95.0% (90.6%; 99.7%)	95.9% (84.7%; 108.7%)
		II	26	N<50	N<50	N<50	N<50	N<50	N<50
		III	51	66.1% (53.9%; 80.9%)	48.0% (35.6%; 64.8%)	39.4% (27.2%; 57.1%)	38.1% (25.8%; 56.3%)	36.4% (24.0%; 55.3%)	16.8% (7.1%; 39.8%)
		IV	26	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	96	50.7% (41.5%; 61.8%)	39.5% (30.7%; 50.8%)	37.3% (28.5%; 49.0%)	35.3% (26.4%; 47.2%)	34.1% (25.0%; 46.3%)	24.3% (12.1%; 48.8%)
Endometrioid carcinoma		All	500	94.8% (92.6%; 97.1%)	91.8% (88.8%; 94.8%)	89.8% (86.4%; 93.4%)	87.1% (82.9%; 91.4%)	84.4% (79.7%; 89.4%)	77.1% (63.2%; 93.9%)
		I	305	100.5% (99.1%; 101.8%)	99.5% (97.1%; 102.0%)	99.2% (96.0%; 102.5%)	98.1% (93.8%; 102.6%)	97.1% (91.9%; 102.5%)	89.6% (69.5%; 115.3%)
		II	60	91.8% (84.4%; 99.8%)	87.1% (77.9%; 97.4%)	87.4% (77.4%; 98.7%)	83.2% (71.6%; 96.8%)	78.1% (64.0%; 95.2%)	33.3% (11.2%; 98.6%)
		III	58	94.2% (87.6%; 101.3%)	80.9% (70.6%; 92.6%)	74.3% (62.9%; 87.7%)	64.1% (51.6%; 79.8%)	57.9% (44.9%; 74.6%)	42.8% (27.9%; 65.7%)
		IV	16	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	61	78.5% (68.3%; 90.2%)	80.6% (70.1%; 92.6%)	76.3% (64.6%; 90.1%)	73.8% (61.2%; 89.1%)	73.4% (59.9%; 89.9%)	92.1% (74.5%; 113.8%)
Clear-cell carcinoma		All	332	87.6% (83.9%; 91.4%)	79.7% (75.2%; 84.5%)	74.9% (69.9%; 80.3%)	73.6% (68.3%; 79.3%)	71.2% (65.4%; 77.5%)	71.1% (62.1%; 81.3%)
		I	198	98.7% (96.5%; 101.0%)	97.6% (94.5%; 100.8%)	96.3% (92.3%; 100.5%)	95.6% (90.9%; 100.5%)	94.9% (89.3%; 100.8%)	97.0% (85.7%; 109.7%)
		II	26	N<50	N<50	N<50	N<50	N<50	N<50
		III	56	84.8% (75.5%; 95.3%)	55.7% (43.7%; 71.0%)	42.6% (31.0%; 58.7%)	41.0% (29.2%; 57.6%)	32.5% (20.9%; 50.6%)	26.5% (13.0%; 54.2%)
		IV	12	N<50	N<50	N<50	N<50	N<50	N<50

Type	Grade	pStage	N at risk	Net Survival Probability, 2014-2023					
				1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		X/NA	40	N<50	N<50	N<50	N<50	N<50	N<50
Adenocarcinoma		All	356	42.3% (37.4%; 48.0%)	34.4% (29.6%; 40.0%)	25.6% (21.0%; 31.0%)	22.5% (18.0%; 28.0%)	17.1% (13.0%; 22.4%)	12.3% (7.6%; 19.9%)
		I	22	N<50	N<50	N<50	N<50	N<50	N<50
		II	5	N<50	N<50	N<50	N<50	N<50	N<50
		III	33	N<50	N<50	N<50	N<50	N<50	N<50
		IV	60	39.2% (28.4%; 54.0%)	26.0% (16.9%; 40.2%)	17.5% (9.9%; 30.8%)	14.4% (7.7%; 27.1%)	9.6% (4.4%; 21.0%)	7.1% (2.1%; 24.1%)
		X/NA	236	32.0% (26.5%; 38.8%)	24.6% (19.5%; 31.2%)	16.2% (11.8%; 22.4%)	13.3% (9.1%; 19.6%)	9.2% (5.6%; 15.3%)	6.0% (2.7%; 13.2%)
Other and unspecified		All	1,063	62.6% (59.7%; 65.7%)	54.7% (51.6%; 58.0%)	49.4% (46.2%; 52.9%)	49.0% (45.7%; 52.7%)	47.5% (43.8%; 51.5%)	51.7% (45.9%; 58.3%)
		I	272	98.2% (96.1%; 100.3%)	98.2% (95.8%; 100.7%)	96.9% (93.7%; 100.2%)	97.4% (93.8%; 101.0%)	99.3% (95.7%; 103.0%)	88.3% (73.8%; 105.8%)
		II	68	87.0% (78.8%; 95.9%)	70.3% (59.6%; 82.9%)	66.3% (54.9%; 80.2%)	66.2% (54.3%; 80.7%)	59.7% (46.5%; 76.7%)	62.9% (47.8%; 82.8%)
		III	115	76.3% (68.6%; 84.7%)	61.8% (53.1%; 71.8%)	45.9% (37.0%; 56.8%)	44.6% (35.5%; 56.0%)	42.0% (32.6%; 54.3%)	62.6% (45.1%; 86.9%)
		IV	51	57.6% (45.4%; 73.2%)	35.2% (24.0%; 51.6%)	30.9% (20.1%; 47.6%)	31.6% (20.5%; 48.6%)	25.0% (14.6%; 42.9%)	FU<10y
		X/NA	557	40.0% (35.9%; 44.4%)	32.0% (28.1%; 36.4%)	27.3% (23.4%; 31.7%)	26.7% (22.7%; 31.3%)	25.4% (21.1%; 30.5%)	29.5% (23.8%; 36.6%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.3. Ovarian cancer survival by type and stage: number at risk and net survival probabilities, 2014-2023

Type	Grade	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2014-2023					
Ovary		All	7,607	78.3% (77.4%; 79.3%)	67.5% (66.4%; 68.7%)	58.1% (56.9%; 59.4%)	51.2% (49.9%; 52.5%)	46.2% (44.8%; 47.6%)	36.1% (33.9%; 38.3%)
		I	1,574	97.4% (96.4%; 98.4%)	96.1% (94.7%; 97.4%)	94.4% (92.7%; 96.2%)	92.7% (90.7%; 94.8%)	92.4% (90.0%; 94.7%)	88.3% (81.7%; 95.4%)
		II	411	88.5% (85.1%; 91.9%)	82.0% (77.9%; 86.3%)	78.4% (73.8%; 83.3%)	74.9% (69.7%; 80.4%)	68.7% (62.8%; 75.2%)	49.0% (35.8%; 67.0%)
		III	2,509	82.3% (80.7%; 83.9%)	68.9% (66.9%; 70.9%)	57.5% (55.4%; 59.7%)	47.4% (45.2%; 49.7%)	40.5% (38.2%; 42.9%)	25.4% (22.6%; 28.6%)
		IV	2,245	66.6% (64.6%; 68.7%)	50.7% (48.5%; 52.9%)	35.7% (33.6%; 38.0%)	27.4% (25.3%; 29.6%)	20.6% (18.6%; 22.7%)	10.9% (8.7%; 13.7%)
		X/NA	875	57.8% (54.5%; 61.4%)	48.6% (45.1%; 52.2%)	42.3% (38.8%; 46.0%)	38.0% (34.6%; 41.8%)	35.2% (31.7%; 39.2%)	30.6% (26.1%; 35.8%)
Serous carcinoma		All	4,824	81.5% (80.3%; 82.7%)	68.2% (66.8%; 69.7%)	56.1% (54.5%; 57.7%)	46.1% (44.5%; 47.8%)	39.6% (37.9%; 41.3%)	25.0% (22.8%; 27.4%)
		I	391	98.0% (96.1%; 100.0%)	95.0% (92.1%; 98.1%)	91.2% (87.4%; 95.2%)	87.9% (83.4%; 92.8%)	86.4% (81.2%; 92.0%)	81.5% (72.0%; 92.2%)
		II	224	93.3% (89.6%; 97.2%)	88.1% (83.2%; 93.2%)	84.5% (78.8%; 90.5%)	78.2% (71.5%; 85.4%)	72.2% (64.7%; 80.5%)	49.1% (33.4%; 72.2%)
		III	2,017	87.6% (86.0%; 89.2%)	74.2% (72.2%; 76.4%)	62.5% (60.2%; 65.0%)	50.5% (48.0%; 53.1%)	42.9% (40.3%; 45.6%)	23.5% (20.4%; 27.0%)
		IV	1,718	75.1% (73.0%; 77.3%)	58.2% (55.7%; 60.7%)	41.5% (39.0%; 44.2%)	31.4% (28.9%; 34.0%)	23.9% (21.5%; 26.5%)	12.7% (10.0%; 16.1%)
		X/NA	474	59.4% (54.9%; 64.2%)	47.2% (42.6%; 52.2%)	37.9% (33.4%; 42.9%)	29.8% (25.5%; 34.8%)	26.3% (22.1%; 31.2%)	15.5% (11.4%; 21.0%)
	Low-grade	All	585	83.9% (80.8%; 87.1%)	76.1% (72.5%; 80.0%)	69.3% (65.3%; 73.6%)	59.3% (54.9%; 64.0%)	52.6% (48.0%; 57.6%)	42.8% (36.7%; 50.0%)
		I	88	99.3% (96.2%; 102.6%)	98.9% (94.6%; 103.5%)	96.0% (89.7%; 102.8%)	94.7% (86.7%; 103.4%)	95.2% (86.6%; 104.6%)	106.1% (93.1%; 120.9%)
		II	26	N<50	N<50	N<50	N<50	N<50	N<50
		III	225	91.2% (87.2%; 95.4%)	83.3% (78.0%; 89.0%)	76.1% (69.9%; 82.8%)	65.3% (58.3%; 73.1%)	56.3% (48.9%; 64.8%)	42.0% (32.9%; 53.5%)
		IV	157	73.7% (67.0%; 81.2%)	60.4% (52.8%; 69.0%)	50.9% (43.2%; 60.0%)	35.8% (28.4%; 45.1%)	25.1% (18.2%; 34.7%)	5.4% (1.6%; 19.0%)
		X/NA	89	65.2% (55.7%; 76.3%)	59.1% (49.2%; 71.0%)	51.6% (41.5%; 64.1%)	40.3% (30.5%; 53.2%)	36.6% (26.9%; 49.8%)	24.1% (14.1%; 41.3%)
	High-grade	All	4,177	81.6% (80.3%; 82.8%)	67.5% (66.0%; 69.0%)	54.5% (52.8%; 56.2%)	44.4% (42.7%; 46.2%)	37.8% (36.1%; 39.7%)	22.1% (19.8%; 24.7%)
		I	299	97.6% (95.2%; 100.1%)	93.8% (90.1%; 97.5%)	89.6% (85.0%; 94.4%)	85.7% (80.2%; 91.5%)	83.5% (77.3%; 90.2%)	73.0% (61.7%; 86.3%)
		II	195	93.2% (89.2%; 97.4%)	87.6% (82.3%; 93.3%)	83.3% (77.1%; 90.0%)	75.9% (68.5%; 84.0%)	69.4% (61.1%; 78.7%)	39.5% (23.5%; 66.3%)
		III	1,786	87.1% (85.5%; 88.8%)	73.1% (70.9%; 75.4%)	60.9% (58.4%; 63.5%)	48.7% (46.1%; 51.5%)	41.3% (38.6%; 44.2%)	21.1% (17.9%; 24.8%)
		IV	1,548	75.2% (73.0%; 77.5%)	58.0% (55.4%; 60.7%)	40.5% (37.9%; 43.3%)	30.9% (28.3%; 33.7%)	23.6% (21.1%; 26.3%)	12.8% (10.0%; 16.5%)

Type	Grade	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2014-2023					
		X/NA	349	60.8% (55.6%; 66.4%)	47.0% (41.7%; 52.9%)	36.3% (31.1%; 42.2%)	28.5% (23.7%; 34.4%)	24.6% (19.9%; 30.4%)	13.7% (9.4%; 20.1%)
	Unspecified	All	62	54.9% (43.4%; 69.3%)	41.8% (30.6%; 57.0%)	37.1% (26.2%; 52.6%)	32.1% (21.6%; 47.6%)	30.8% (20.4%; 46.5%)	25.5% (14.8%; 43.9%)
		I	4	N<50	N<50	N<50	N<50	N<50	N<50
		II	3	N<50	N<50	N<50	N<50	N<50	N<50
		III	6	N<50	N<50	N<50	N<50	N<50	N<50
		IV	13	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	36	N<50	N<50	N<50	N<50	N<50	N<50
Mucinous carcinoma		All	541	83.8% (80.6%; 87.1%)	78.6% (74.9%; 82.5%)	75.6% (71.5%; 79.8%)	74.3% (70.0%; 78.9%)	72.4% (67.8%; 77.4%)	65.6% (56.7%; 75.9%)
		I	346	98.5% (96.7%; 100.4%)	97.8% (95.3%; 100.5%)	97.6% (94.6%; 100.7%)	96.3% (92.6%; 100.1%)	96.0% (91.7%; 100.4%)	96.3% (85.1%; 109.0%)
		II	25	N<50	N<50	N<50	N<50	N<50	N<50
		III	68	60.0% (49.2%; 73.3%)	41.5% (30.8%; 55.9%)	34.8% (24.4%; 49.7%)	33.9% (23.3%; 49.2%)	32.7% (22.0%; 48.5%)	17.1% (7.5%; 39.4%)
		IV	61	38.7% (28.2%; 53.1%)	25.5% (16.5%; 39.4%)	16.7% (9.4%; 29.6%)	15.1% (8.2%; 27.8%)	11.4% (5.5%; 23.5%)	3.3% (0.7%; 15.1%)
		X/NA	41	N<50	N<50	N<50	N<50	N<50	N<50
Endometrioid carcinoma		All	500	94.8% (92.6%; 97.1%)	91.8% (88.8%; 94.8%)	89.8% (86.4%; 93.4%)	87.1% (82.9%; 91.4%)	84.4% (79.7%; 89.4%)	77.1% (63.2%; 93.9%)
		I	305	100.0% (98.5%; 101.6%)	99.0% (96.5%; 101.6%)	98.6% (95.3%; 101.9%)	98.1% (93.9%; 102.4%)	97.8% (92.9%; 102.9%)	89.3% (68.9%; 115.8%)
		II	55	94.7% (87.9%; 101.9%)	91.5% (82.8%; 101.0%)	91.9% (82.2%; 102.7%)	87.5% (75.7%; 101.2%)	80.8% (65.5%; 99.7%)	37.3% (12.7%; 109.6%)
		III	68	88.2% (80.2%; 97.0%)	77.6% (67.5%; 89.3%)	66.9% (55.4%; 80.7%)	56.2% (44.1%; 71.6%)	53.2% (41.0%; 69.1%)	47.1% (32.2%; 69.0%)
		IV	35	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	37	N<50	N<50	N<50	N<50	N<50	N<50
Clear-cell carcinoma		All	332	87.6% (83.9%; 91.4%)	79.7% (75.2%; 84.5%)	74.9% (69.9%; 80.3%)	73.6% (68.3%; 79.3%)	71.2% (65.4%; 77.5%)	71.1% (62.1%; 81.3%)
		I	200	98.3% (95.9%; 100.7%)	97.2% (93.9%; 100.5%)	95.9% (91.8%; 100.1%)	95.1% (90.4%; 100.1%)	94.4% (88.8%; 100.4%)	95.0% (83.8%; 107.9%)
		II	25	N<50	N<50	N<50	N<50	N<50	N<50
		III	60	77.6% (67.4%; 89.3%)	55.7% (44.0%; 70.4%)	43.7% (32.3%; 59.2%)	42.4% (30.8%; 58.4%)	32.3% (21.1%; 49.7%)	26.5% (13.1%; 53.7%)
		IV	33	N<50	N<50	N<50	N<50	N<50	N<50

| Type | Grade | Stage | N at risk | Net Survival Probability, 2014-2023 | | | | | |
				1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		X/NA	14	N<50	N<50	N<50	N<50	N<50	N<50
Adenocarcinoma		All	356	42.3% (37.4%; 48.0%)	34.4% (29.6%; 40.0%)	25.6% (21.0%; 31.0%)	22.5% (18.0%; 28.0%)	17.1% (13.0%; 22.4%)	12.3% (7.6%; 19.9%)
		I	24	N<50	N<50	N<50	N<50	N<50	N<50
		II	4	N<50	N<50	N<50	N<50	N<50	N<50
		III	77	46.3% (36.3%; 59.1%)	37.7% (28.1%; 50.7%)	28.9% (19.9%; 42.0%)	27.3% (18.3%; 40.8%)	20.5% (12.5%; 33.6%)	15.4% (8.0%; 29.8%)
		IV	185	36.2% (29.7%; 44.0%)	27.1% (21.2%; 34.6%)	15.5% (10.8%; 22.2%)	11.3% (7.2%; 17.8%)	5.0% (2.5%; 10.2%)	2.5% (0.7%; 8.9%)
		X/NA	66	34.5% (24.5%; 48.6%)	27.1% (17.8%; 41.2%)	26.4% (17.0%; 40.8%)	27.6% (17.8%; 42.7%)	26.4% (16.5%; 42.2%)	22.5% (11.6%; 43.7%)
Other and unspecified		All	1,063	62.6% (59.7%; 65.7%)	54.7% (51.6%; 58.0%)	49.4% (46.2%; 52.9%)	49.0% (45.7%; 52.7%)	47.5% (43.8%; 51.5%)	51.7% (45.9%; 58.3%)
		I	310	92.6% (89.4%; 95.9%)	92.0% (88.4%; 95.7%)	90.0% (85.7%; 94.5%)	88.9% (84.0%; 94.1%)	90.7% (85.7%; 95.9%)	81.7% (68.4%; 97.7%)
		II	78	74.1% (64.3%; 85.3%)	64.4% (53.7%; 77.2%)	61.7% (50.0%; 76.1%)	63.3% (51.0%; 78.6%)	56.8% (43.1%; 75.0%)	60.6% (44.7%; 82.1%)
		III	219	52.2% (45.8%; 59.5%)	39.8% (33.5%; 47.3%)	30.1% (24.1%; 37.5%)	29.0% (22.9%; 36.7%)	25.8% (19.3%; 34.5%)	37.6% (26.2%; 53.8%)
		IV	213	35.5% (29.5%; 42.7%)	19.8% (14.9%; 26.3%)	12.3% (8.3%; 18.0%)	11.9% (8.0%; 17.7%)	10.6% (6.8%; 16.4%)	FU<10y
		X/NA	243	54.0% (47.8%; 61.1%)	48.2% (41.9%; 55.5%)	44.6% (38.1%; 52.1%)	45.1% (38.4%; 52.9%)	43.8% (36.6%; 52.5%)	52.0% (42.0%; 64.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Ovarian cancer survival trends: by tumour stage

5.1.1. Ovarian cancer survival trends by stage: number at risk and net survival probabilities, 2004-2023

Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			Net Survival Probability		
2004-2008	**All**	4,529	77.8% (76.6%; 79.1%)	56.2% (54.7%; 57.8%)	44.1% (42.5%; 45.8%)
	I	727	97.3% (95.8%; 98.9%)	92.9% (90.3%; 95.5%)	90.2% (86.9%; 93.6%)
	II	249	85.8% (81.3%; 90.6%)	68.4% (62.4%; 75.1%)	59.0% (52.5%; 66.3%)
	III	1,102	82.2% (79.9%; 84.6%)	54.4% (51.3%; 57.6%)	36.2% (33.3%; 39.4%)
	IV	716	63.5% (59.9%; 67.2%)	32.5% (29.1%; 36.4%)	18.1% (15.3%; 21.5%)
	X/NA	1,736	71.7% (69.5%; 74.0%)	50.1% (47.7%; 52.7%)	38.5% (36.0%; 41.1%)
2009-2013	**All**	4,017	77.2% (75.8%; 78.5%)	54.5% (52.9%; 56.2%)	42.7% (41.0%; 44.5%)
	I	668	96.4% (94.7%; 98.1%)	90.2% (87.3%; 93.1%)	88.0% (84.5%; 91.7%)
	II	227	89.4% (85.1%; 93.9%)	75.9% (69.7%; 82.6%)	64.2% (57.1%; 72.2%)
	III	1,185	82.8% (80.6%; 85.1%)	54.4% (51.5%; 57.5%)	35.7% (32.9%; 38.8%)
	IV	883	67.3% (64.2%; 70.6%)	36.7% (33.5%; 40.2%)	23.3% (20.4%; 26.6%)
	X/NA	1,054	64.2% (61.3%; 67.3%)	42.4% (39.3%; 45.7%)	33.4% (30.3%; 36.8%)
2014-2018	**All**	3,851	78.5% (77.2%; 79.9%)	58.6% (57.0%; 60.4%)	46.2% (44.5%; 48.0%)
	I	740	97.8% (96.4%; 99.2%)	95.1% (92.8%; 97.4%)	92.1% (89.0%; 95.2%)
	II	203	90.3% (85.9%; 94.9%)	77.4% (71.1%; 84.2%)	68.9% (61.6%; 77.2%)
	III	1,307	83.9% (81.8%; 86.0%)	57.6% (54.7%; 60.5%)	39.5% (36.7%; 42.5%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	1,011	65.3% (62.3%; 68.4%)	37.4% (34.4%; 40.7%)	22.2% (19.6%; 25.2%)
	X/NA	593	60.9% (56.9%; 65.1%)	45.1% (40.9%; 49.6%)	36.8% (32.6%; 41.6%)
2019-2023	All	3,757	78.2% (76.8%; 79.6%)	57.4% (55.6%; 59.2%)	46.4% (44.2%; 48.8%)
	I	834	97.1% (95.6%; 98.6%)	93.7% (91.1%; 96.3%)	93.9% (90.6%; 97.3%)
	II	208	86.7% (81.7%; 91.9%)	79.7% (73.1%; 87.0%)	66.9% (56.5%; 79.1%)
	III	1,202	80.5% (78.2%; 82.9%)	57.5% (54.4%; 60.9%)	42.9% (39.0%; 47.3%)
	IV	1,234	67.7% (65.1%; 70.5%)	33.8% (30.9%; 37.0%)	18.2% (15.3%; 21.8%)
	X/NA	282	51.5% (45.8%; 58.0%)	36.3% (30.5%; 43.2%)	33.3% (27.1%; 40.8%)

5.2. Ovarian cancer survival trends: by tumour type and tumour stage

5.2.1. Ovarian cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2023

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	Serous carcinoma		**All**	2,251	85.3% (83.8%; 86.9%)	58.0% (55.9%; 60.2%)	40.3% (38.1%; 42.5%)
			I	209	98.5% (96.0%; 101.0%)	95.4% (91.0%; 100.0%)	88.2% (81.7%; 95.2%)
			II	142	88.7% (83.1%; 94.5%)	71.1% (63.4%; 79.7%)	55.9% (47.6%; 65.7%)
			III	753	89.8% (87.5%; 92.2%)	59.2% (55.5%; 63.0%)	38.2% (34.6%; 42.1%)
			IV	395	77.3% (73.1%; 81.7%)	40.2% (35.5%; 45.6%)	21.6% (17.7%; 26.4%)
			X/NA	752	80.7% (77.8%; 83.7%)	53.3% (49.6%; 57.2%)	35.8% (32.3%; 39.7%)
		Low-grade	**All**	1,330	86.4% (84.4%; 88.4%)	57.3% (54.5%; 60.2%)	39.4% (36.6%; 42.3%)
			I	108	101.1% (99.2%; 103.0%)	97.6% (91.8%; 103.7%)	89.3% (80.3%; 99.4%)
			II	93	86.4% (79.2%; 94.4%)	68.7% (59.1%; 79.9%)	54.7% (44.5%; 67.3%)
			III	460	91.6% (88.9%; 94.4%)	58.6% (54.0%; 63.6%)	38.6% (34.1%; 43.6%)
			IV	233	77.3% (71.9%; 83.2%)	42.6% (36.5%; 49.9%)	21.9% (16.9%; 28.3%)
			X/NA	436	82.1% (78.4%; 86.0%)	51.3% (46.6%; 56.5%)	33.9% (29.5%; 39.0%)
		High-grade	**All**	244	87.4% (83.0%; 91.9%)	60.8% (54.6%; 67.7%)	37.9% (31.9%; 45.1%)
			I	15	N<50	N<50	N<50
			II	16	N<50	N<50	N<50
			III	81	85.1% (77.3%; 93.6%)	60.4% (50.1%; 72.8%)	36.8% (27.2%; 49.9%)
			IV	59	81.0% (71.2%; 92.1%)	46.3% (34.8%; 61.5%)	27.6% (17.9%; 42.6%)
			X/NA	73	90.5% (83.5%; 98.1%)	61.3% (50.4%; 74.5%)	35.1% (25.3%; 48.8%)
		Unspecified	**All**	677	82.4% (79.5%; 85.5%)	58.4% (54.5%; 62.5%)	42.9% (39.0%; 47.1%)
			I	86	94.6% (89.2%; 100.2%)	91.7% (84.3%; 99.6%)	86.3% (76.8%; 96.9%)

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	33	N<50	N<50	N<50
			III	212	87.8% (83.2%; 92.6%)	60.0% (53.3%; 67.5%)	37.8% (31.4%; 45.6%)
			IV	103	75.0% (66.9%; 84.2%)	31.4% (23.4%; 42.1%)	17.7% (11.5%; 27.4%)
			X/NA	243	75.3% (69.9%; 81.2%)	54.4% (48.2%; 61.5%)	39.6% (33.4%; 46.8%)
	Mucinous carcinoma		All	448	77.7% (73.8%; 81.9%)	66.8% (62.2%; 71.8%)	62.6% (57.6%; 68.0%)
			I	173	95.8% (92.3%; 99.5%)	90.9% (85.2%; 96.9%)	90.9% (84.3%; 98.0%)
			II	25	N<50	N<50	N<50
			III	45	N<50	N<50	N<50
			IV	52	43.0% (31.3%; 59.1%)	22.6% (13.5%; 37.6%)	17.5% (9.5%; 32.3%)
			X/NA	153	75.5% (68.7%; 82.9%)	65.7% (58.1%; 74.2%)	59.2% (51.2%; 68.4%)
	Endometrioid carcinoma		All	382	91.4% (88.4%; 94.6%)	79.6% (75.1%; 84.3%)	73.8% (68.6%; 79.3%)
			I	147	99.5% (97.2%; 101.9%)	95.2% (90.3%; 100.4%)	91.0% (84.2%; 98.3%)
			II	31	N<50	N<50	N<50
			III	68	86.8% (78.6%; 95.8%)	71.3% (60.3%; 84.2%)	54.8% (42.7%; 70.3%)
			IV	25	N<50	N<50	N<50
			X/NA	111	89.5% (83.6%; 95.8%)	75.4% (67.0%; 84.8%)	71.7% (62.8%; 82.0%)
	Clear-cell carcinoma		All	177	89.9% (85.3%; 94.7%)	73.7% (67.0%; 81.0%)	67.6% (60.3%; 75.9%)
			I	77	98.7% (95.2%; 102.4%)	88.0% (79.8%; 97.0%)	89.9% (81.2%; 99.5%)
			II	11	N<50	N<50	N<50
			III	24	N<50	N<50	N<50
			IV	6	N<50	N<50	N<50
			X/NA	59	84.0% (74.9%; 94.2%)	68.4% (57.1%; 82.1%)	58.9% (46.9%; 74.1%)
	Adenocarcinoma		All	765	56.8% (53.3%; 60.6%)	34.8% (31.3%; 38.6%)	25.4% (22.2%; 29.1%)
			I	42	N<50	N<50	N<50

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	16	N<50	N<50	N<50
			III	135	57.8% (49.8%; 67.1%)	36.8% (29.0%; 46.6%)	24.8% (18.0%; 34.3%)
			IV	169	45.6% (38.6%; 54.0%)	19.4% (14.1%; 26.8%)	9.5% (5.7%; 15.8%)
			X/NA	403	56.2% (51.4%; 61.4%)	32.9% (28.4%; 38.2%)	23.8% (19.7%; 28.9%)
	Other and unspecified		All	506	62.1% (57.8%; 66.6%)	47.6% (43.1%; 52.6%)	42.5% (37.7%; 47.9%)
			I	79	93.7% (87.9%; 99.8%)	90.4% (82.8%; 98.7%)	91.8% (83.2%; 101.4%)
			II	24	N<50	N<50	N<50
			III	77	58.3% (48.1%; 70.6%)	33.1% (23.5%; 46.7%)	25.5% (16.9%; 38.6%)
			IV	69	42.8% (32.3%; 56.8%)	26.3% (16.9%; 40.8%)	16.0% (7.8%; 32.5%)
			X/NA	258	57.1% (51.2%; 63.7%)	43.3% (37.2%; 50.5%)	37.6% (31.4%; 45.0%)
2009-2013	Serous carcinoma		All	2,356	83.0% (81.4%; 84.6%)	56.8% (54.7%; 59.0%)	40.5% (38.4%; 42.7%)
			I	215	94.5% (91.0%; 98.2%)	89.9% (84.7%; 95.4%)	84.5% (77.7%; 91.8%)
			II	144	88.3% (82.7%; 94.2%)	74.8% (67.1%; 83.3%)	61.4% (52.9%; 71.2%)
			III	899	88.9% (86.7%; 91.1%)	59.5% (56.1%; 63.0%)	38.8% (35.5%; 42.4%)
			IV	584	78.0% (74.6%; 81.6%)	45.4% (41.3%; 49.9%)	27.9% (24.3%; 32.1%)
			X/NA	514	71.9% (68.0%; 76.1%)	46.3% (41.9%; 51.1%)	33.4% (29.2%; 38.1%)
		Low-grade	All	1,373	82.7% (80.6%; 84.9%)	54.8% (52.0%; 57.7%)	37.6% (34.9%; 40.5%)
			I	105	93.3% (87.9%; 98.9%)	88.2% (80.8%; 96.4%)	78.3% (68.6%; 89.5%)
			II	77	87.3% (79.6%; 95.8%)	73.8% (63.4%; 85.9%)	59.5% (48.1%; 73.5%)
			III	559	88.1% (85.3%; 91.1%)	58.2% (54.0%; 62.8%)	36.4% (32.4%; 41.0%)
			IV	338	80.8% (76.5%; 85.3%)	45.0% (39.8%; 50.9%)	27.4% (22.8%; 32.9%)
			X/NA	294	69.6% (64.4%; 75.3%)	42.4% (36.8%; 48.8%)	31.3% (26.1%; 37.5%)
		High-grade	All	250	90.5% (86.6%; 94.5%)	67.2% (61.2%; 73.7%)	54.4% (48.0%; 61.6%)
			I	13	N<50	N<50	N<50

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	10	N<50	N<50	N<50
			III	104	97.6% (93.9%; 101.4%)	68.2% (59.3%; 78.5%)	53.0% (43.4%; 64.6%)
			IV	78	80.7% (72.1%; 90.4%)	53.5% (43.1%; 66.5%)	43.2% (33.0%; 56.7%)
			X/NA	45	N<50	N<50	N<50
		Unspecified	All	733	80.9% (77.9%; 84.0%)	57.1% (53.4%; 61.1%)	41.1% (37.3%; 45.2%)
			I	97	95.0% (89.9%; 100.3%)	92.0% (84.6%; 100.1%)	90.3% (80.7%; 101.1%)
			II	57	87.2% (78.4%; 97.0%)	70.9% (58.9%; 85.3%)	57.7% (45.0%; 74.2%)
			III	236	86.9% (82.4%; 91.6%)	58.6% (52.3%; 65.7%)	38.2% (32.1%; 45.4%)
			IV	168	71.2% (64.4%; 78.7%)	42.4% (35.2%; 51.2%)	21.9% (16.1%; 29.8%)
			X/NA	175	72.3% (65.6%; 79.5%)	45.5% (38.3%; 54.1%)	30.7% (24.1%; 39.3%)
	Mucinous carcinoma		All	305	78.7% (74.0%; 83.6%)	65.4% (59.9%; 71.3%)	60.6% (54.8%; 67.1%)
			I	155	97.3% (94.2%; 100.5%)	93.3% (88.4%; 98.6%)	90.2% (83.8%; 97.1%)
			II	11	N<50	N<50	N<50
			III	44	N<50	N<50	N<50
			IV	40	N<50	N<50	N<50
			X/NA	55	66.8% (55.2%; 80.9%)	45.3% (33.4%; 61.5%)	37.5% (25.9%; 54.1%)
	Endometrioid carcinoma		All	238	93.6% (90.1%; 97.2%)	81.1% (75.5%; 87.0%)	73.5% (67.0%; 80.6%)
			I	115	101.8% (101.8%; 101.8%)	94.1% (88.1%; 100.5%)	95.6% (88.5%; 103.2%)
			II	19	N<50	N<50	N<50
			III	46	N<50	N<50	N<50
			IV	20	N<50	N<50	N<50
			X/NA	38	N<50	N<50	N<50
	Clear-cell carcinoma		All	137	84.6% (78.5%; 91.2%)	71.1% (63.3%; 80.0%)	64.9% (56.3%; 74.8%)
			I	62	98.4% (94.0%; 102.9%)	92.5% (84.2%; 101.6%)	96.2% (87.1%; 106.3%)

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
						Net Survival Probability	
			II	12	N<50	N<50	N<50
			III	25	N<50	N<50	N<50
			IV	18	N<50	N<50	N<50
			X/NA	20	N<50	N<50	N<50
	Adenocarcinoma		All	510	54.2% (49.9%; 58.9%)	26.3% (22.6%; 30.7%)	20.4% (16.9%; 24.7%)
			I	34	N<50	N<50	N<50
			II	11	N<50	N<50	N<50
			III	93	64.9% (55.6%; 75.7%)	27.9% (19.9%; 39.2%)	19.8% (12.9%; 30.3%)
			IV	142	47.3% (39.6%; 56.6%)	16.4% (11.1%; 24.2%)	9.4% (5.5%; 16.1%)
			X/NA	230	46.1% (40.0%; 53.3%)	20.7% (15.8%; 27.1%)	15.8% (11.3%; 21.9%)
	Other and unspecified		All	471	61.6% (57.2%; 66.3%)	48.6% (43.9%; 53.7%)	44.4% (39.1%; 50.5%)
			I	87	91.0% (84.7%; 97.7%)	80.2% (71.4%; 90.2%)	78.1% (68.4%; 89.3%)
			II	30	N<50	N<50	N<50
			III	78	58.1% (47.9%; 70.4%)	38.9% (29.1%; 52.0%)	29.4% (20.4%; 42.4%)
			IV	79	31.4% (22.5%; 43.6%)	15.1% (8.7%; 26.2%)	10.2% (3.9%; 26.3%)
			X/NA	197	57.3% (50.6%; 65.0%)	47.4% (40.3%; 55.9%)	45.8% (37.4%; 56.1%)
2014-2018	Serous carcinoma		All	2,453	82.0% (80.4%; 83.6%)	57.1% (55.1%; 59.3%)	39.8% (37.7%; 42.0%)
			I	200	98.8% (96.4%; 101.2%)	92.9% (88.0%; 98.0%)	84.4% (77.6%; 91.8%)
			II	120	95.0% (90.4%; 99.7%)	85.6% (78.4%; 93.5%)	74.7% (65.6%; 85.1%)
			III	1,037	89.1% (87.1%; 91.2%)	62.5% (59.4%; 65.8%)	41.5% (38.3%; 44.9%)
			IV	761	73.9% (70.7%; 77.2%)	42.9% (39.3%; 46.8%)	25.1% (22.0%; 28.7%)
			X/NA	335	63.6% (58.5%; 69.3%)	41.2% (35.9%; 47.3%)	28.8% (23.9%; 34.7%)
		Low-grade	All	383	81.1% (77.1%; 85.4%)	65.3% (60.4%; 70.7%)	46.9% (41.7%; 52.7%)
			I	54	97.7% (92.6%; 103.0%)	91.5% (82.6%; 101.4%)	88.3% (77.1%; 101.1%)

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	17	N<50	N<50	N<50
			III	140	92.2% (87.4%; 97.3%)	74.0% (66.3%; 82.5%)	50.1% (41.8%; 60.1%)
			IV	96	66.6% (57.6%; 76.9%)	44.6% (35.4%; 56.3%)	21.2% (14.2%; 31.6%)
			X/NA	76	65.7% (55.5%; 77.7%)	51.3% (40.5%; 64.9%)	34.8% (24.8%; 48.9%)
		High-grade	All	2,027	82.4% (80.7%; 84.2%)	55.8% (53.6%; 58.2%)	38.5% (36.2%; 40.9%)
			I	143	99.2% (96.4%; 102.0%)	93.2% (87.4%; 99.4%)	82.5% (74.3%; 91.7%)
			II	101	95.9% (91.2%; 100.8%)	84.4% (76.4%; 93.4%)	72.1% (62.0%; 84.0%)
			III	891	88.7% (86.4%; 91.0%)	60.8% (57.4%; 64.4%)	40.3% (36.9%; 44.0%)
			IV	654	74.9% (71.5%; 78.5%)	42.7% (38.9%; 46.9%)	25.4% (22.1%; 29.3%)
			X/NA	238	63.8% (57.7%; 70.5%)	38.7% (32.6%; 45.9%)	26.9% (21.4%; 33.9%)
		Unspecified	All	43	N<50	N<50	N<50
			I	3	N<50	N<50	N<50
			II	2	N<50	N<50	N<50
			III	6	N<50	N<50	N<50
			IV	11	N<50	N<50	N<50
			X/NA	21	N<50	N<50	N<50
	Mucinous carcinoma		All	263	83.7% (79.1%; 88.5%)	72.4% (66.8%; 78.6%)	69.2% (63.0%; 76.0%)
			I	154	97.8% (95.1%; 100.7%)	95.8% (91.4%; 100.4%)	93.5% (87.7%; 99.6%)
			II	14	N<50	N<50	N<50
			III	40	N<50	N<50	N<50
			IV	25	N<50	N<50	N<50
			X/NA	30	N<50	N<50	N<50
	Endometrioid carcinoma		All	275	94.6% (91.5%; 97.7%)	89.7% (85.2%; 94.4%)	84.6% (79.0%; 90.7%)
			I	161	99.0% (96.5%; 101.7%)	97.4% (92.9%; 102.0%)	97.8% (92.0%; 103.8%)

Period	Type	Grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
						Net Survival Probability	
			II	26	N<50	N<50	N<50
			III	45	N<50	N<50	N<50
			IV	14	N<50	N<50	N<50
			X/NA	29	N<50	N<50	N<50
	Clear-cell carcinoma		All	174	89.1% (84.3%; 94.2%)	79.4% (72.9%; 86.4%)	76.3% (69.1%; 84.4%)
			I	106	101.3% (101.3%; 101.3%)	99.5% (95.3%; 104.0%)	99.4% (93.3%; 105.8%)
			II	9	N<50	N<50	N<50
			III	33	N<50	N<50	N<50
			IV	14	N<50	N<50	N<50
			X/NA	12	N<50	N<50	N<50
	Adenocarcinoma		All	188	41.3% (34.7%; 49.2%)	25.5% (19.7%; 33.0%)	17.4% (12.4%; 24.3%)
			I	9	N<50	N<50	N<50
			II	2	N<50	N<50	N<50
			III	47	N<50	N<50	N<50
			IV	94	38.3% (29.4%; 49.7%)	17.6% (11.2%; 27.9%)	7.2% (3.4%; 15.3%)
			X/NA	36	N<50	N<50	N<50
	Other and unspecified		All	503	60.2% (55.9%; 64.9%)	47.1% (42.6%; 52.0%)	45.1% (40.2%; 50.5%)
			I	112	90.5% (84.8%; 96.6%)	89.9% (83.3%; 97.1%)	88.7% (80.7%; 97.5%)
			II	32	N<50	N<50	N<50
			III	105	58.7% (49.7%; 69.3%)	33.5% (25.1%; 44.6%)	29.9% (21.4%; 41.8%)
			IV	103	33.6% (25.5%; 44.3%)	14.3% (8.8%; 23.1%)	12.5% (7.3%; 21.4%)
			X/NA	151	55.0% (47.2%; 64.0%)	45.9% (37.8%; 55.7%)	44.0% (35.1%; 55.2%)
2019-2023	Serous carcinoma		All	2,371	81.0% (79.3%; 82.7%)	54.6% (52.3%; 57.0%)	40.0% (37.3%; 42.9%)
			I	191	97.3% (94.2%; 100.5%)	89.2% (83.3%; 95.5%)	92.4% (85.8%; 99.5%)

Period	Type	Grade	Stage	N at risk	1-y	(95%CI)	3-y (95%CI)	5-y (95%CI)
					Net Survival Probability			
			II	104	91.3%	(85.4%; 97.7%)	83.2% (74.7%; 92.8%)	68.4% (56.3%; 83.2%)
			III	980	85.9%	(83.6%; 88.3%)	62.5% (59.1%; 66.2%)	46.2% (41.9%; 51.0%)
			IV	957	76.1%	(73.3%; 79.0%)	40.0% (36.5%; 43.7%)	22.4% (18.8%; 26.8%)
			X/NA	139	49.2%	(41.3%; 58.6%)	29.9% (22.3%; 39.9%)	20.4% (13.4%; 30.9%)
		Low-grade	**All**	202	89.0%	(84.5%; 93.8%)	76.8% (70.1%; 84.0%)	69.2% (60.8%; 78.9%)
			I	34	N<50		N<50	N<50
			II	9	N<50		N<50	N<50
			III	85	89.5%	(82.9%; 96.8%)	79.7% (69.7%; 91.1%)	74.0% (61.2%; 89.5%)
			IV	61	85.0%	(76.1%; 94.9%)	60.5% (48.2%; 75.9%)	35.9% (21.4%; 60.4%)
			X/NA	13	N<50		N<50	N<50
		High-grade	**All**	2,150	80.7%	(79.0%; 82.5%)	52.8% (50.4%; 55.4%)	37.5% (34.6%; 40.5%)
			I	156	96.2%	(92.4%; 100.1%)	85.7% (78.8%; 93.3%)	88.2% (80.4%; 96.7%)
			II	94	90.3%	(83.8%; 97.3%)	82.3% (73.1%; 92.6%)	65.5% (52.5%; 81.7%)
			III	895	85.6%	(83.2%; 88.1%)	60.9% (57.3%; 64.8%)	43.3% (38.8%; 48.4%)
			IV	894	75.4%	(72.5%; 78.5%)	38.4% (34.9%; 42.3%)	21.7% (18.0%; 26.1%)
			X/NA	111	54.4%	(45.5%; 64.9%)	31.1% (22.7%; 42.8%)	19.5% (12.0%; 31.7%)
		Unspecified	**All**	19	N<50		N<50	N<50
			I	1	N<50		N<50	N<50
			II	1	N<50		N<50	N<50
			IV	2	N<50		N<50	N<50
			X/NA	15	N<50		N<50	N<50
	Mucinous carcinoma		**All**	278	83.8%	(79.4%; 88.5%)	79.1% (73.6%; 85.0%)	75.9% (68.7%; 84.0%)
			I	192	99.1%	(96.7%; 101.4%)	99.2% (95.2%; 103.4%)	99.5% (94.0%; 105.2%)
			II	11	N<50		N<50	N<50

Period	Type	Grade	Stage	N at risk	1-y (95%CI)		3-y (95%CI)	5-y (95%CI)
					Net Survival Probability			
			III	28	N<50		N<50	N<50
			IV	36	N<50		N<50	N<50
			X/NA	11	N<50		N<50	N<50
	Endometrioid carcinoma		All	225	95.2%	(91.9%; 98.5%)	90.3% (85.0%; 95.9%)	85.6% (77.8%; 94.3%)
			I	144	101.1%	(99.8%; 102.5%)	100.1% (95.4%; 105.0%)	97.1% (88.0%; 107.1%)
			II	29	N<50		N<50	N<50
			III	23	N<50		N<50	N<50
			IV	21	N<50		N<50	N<50
			X/NA	8	N<50		N<50	N<50
	Clear-cell carcinoma		All	158	85.9%	(80.4%; 91.8%)	69.7% (62.2%; 78.2%)	64.2% (55.0%; 74.9%)
			I	94	94.8%	(89.9%; 100.0%)	91.5% (84.5%; 99.1%)	86.3% (75.6%; 98.4%)
			II	16	N<50		N<50	N<50
			III	27	N<50		N<50	N<50
			IV	19	N<50		N<50	N<50
			X/NA	2	N<50		N<50	N<50
	Adenocarcinoma		All	168	43.5%	(36.4%; 52.0%)	25.0% (18.5%; 33.9%)	15.7% (9.6%; 25.7%)
			I	15	N<50		N<50	N<50
			II	2	N<50		N<50	N<50
			III	30	N<50		N<50	N<50
			IV	91	34.0%	(25.4%; 45.5%)	12.8% (7.1%; 23.1%)	1.8% (0.4%; 9.1%)
			X/NA	30	N<50		N<50	N<50
	Other and unspecified		All	560	64.8%	(60.8%; 69.0%)	51.3% (46.8%; 56.3%)	49.4% (43.5%; 56.2%)
			I	198	93.7%	(90.0%; 97.6%)	89.5% (83.7%; 95.6%)	91.5% (85.2%; 98.2%)
			II	46	N<50		N<50	N<50

Period	Type	Grade	Stage	Net Survival Probability				
				N at risk	1-y	(95%CI)	3-y (95%CI)	5-y (95%CI)
			III	114	46.2%	(37.7%; 56.6%)	26.8% (19.2%; 37.5%)	20.1% (10.7%; 37.7%)
			IV	110	37.3%	(29.1%; 47.7%)	9.8% (5.2%; 18.5%)	8.7% (4.4%; 17.4%)
			X/NA	92	52.6%	(43.0%; 64.2%)	42.1% (32.4%; 54.7%)	44.9% (34.5%; 58.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Ovarian cancer mortality: by region

6.1.1. Ovarian cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Belgium	0	0	0	0	0	2	1	2	8	9	26	30	42	74	81	95	98	83	40	11	602	9.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.3]	[0.5]	[2.1]	[2.4]	[6.7]	[7.5]	[11.3]	[22.7]	[27.3]	[44.5]	[53.0]	[61.4]	[60.4]	[57.2]	[10.3]	(8.5; 10.0)
Brussels	0	0	0	0	0	0	0	0	1	3	4	1	1	3	6	8	5	4	3	1	40	7.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[7.5]	[10.8]	[3.0]	[3.4]	[12.2]	[27.8]	[49.2]	[36.5]	[39.4]	[52.3]	[51.1]	[6.4]	(5.4; 10.4)
Flanders	0	0	0	0	0	0	1	2	3	4	15	19	27	55	47	60	68	57	27	7	392	9.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[1.4]	[1.9]	[6.6]	[7.9]	[12.2]	[28.5]	[27.0]	[45.0]	[58.6]	[67.1]	[67.3]	[62.3]	[11.7]	(8.9; 10.9)
Wallonia	0	0	0	0	0	2	0	0	4	2	7	10	14	16	28	27	25	22	10	3	170	8.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.0]	[0.0]	[3.5]	[1.6]	[5.6]	[7.8]	[11.6]	[14.7]	[27.8]	[42.4]	[45.3]	[54.9]	[49.0]	[49.7]	[9.1]	(7.1; 9.7)

Belgian Cancer Registry

7.1. Ovarian cancer mortality trends: by region

7.1.1. Ovarian cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	682	669	663	709	668	687	696	654	678	616	601	665	565	606	574	611	585	602		
	CR	12.8	12.5	12.4	13.1	12.3	12.5	12.6	11.7	12.1	10.9	10.6	11.7	9.9	10.5	9.9	10.5	10.0	10.3		
	ESR2013	13.0	12.5	12.4	13.0	12.0	12.2	12.2	11.2	11.5	10.4	10.1	11.1	9.3	9.7	9.1	9.6	9.2	9.3	-2.3 (-2.7; -1.9)	2004-2021
Brussels	**N**	66	38	56	55	60	56	55	54	56	45	54	51	41	37	53	35	36	40		
	CR	12.7	7.3	10.6	10.3	11.1	10.1	9.8	9.4	9.6	7.6	9.0	8.5	6.7	6.1	8.7	5.7	5.8	6.4		
	ESR2013	12.9	7.4	11.8	11.3	12.0	11.6	10.7	10.6	10.7	8.7	10.3	10.3	7.8	7.2	10.7	6.7	7.3	7.9	-2.5 (-4.0; -0.9)	2004-2021
Flanders	**N**	386	430	396	427	398	412	418	388	394	369	370	376	360	364	352	386	355	392		
	CR	12.7	14.0	12.9	13.8	12.7	13.1	13.2	12.2	12.3	11.4	11.4	11.5	11.0	11.0	10.6	11.6	10.6	11.7		
	ESR2013	12.7	13.9	12.7	13.4	12.1	12.4	12.4	11.3	11.2	10.5	10.5	10.4	9.8	9.6	9.1	10.0	9.1	9.9	-2.3 (-2.8; -1.9)	2004-2021
Wallonia	**N**	230	201	211	227	210	219	223	212	228	202	177	238	164	205	169	190	194	170		
	CR	13.2	11.5	12.0	12.8	11.8	12.3	12.4	11.7	12.5	11.0	9.6	12.9	8.9	11.1	9.1	10.2	10.4	9.1		
	ESR2013	13.4	11.5	12.0	12.7	12.0	12.0	12.2	11.1	12.3	10.7	9.1	12.6	8.6	10.6	8.6	9.5	9.8	8.4	-2.2 (-3.1; -1.3)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025